Introduction
It has long been recognized that adenosine interacts with mast cells (1) . Adenosine does not produce direct activation of mast cells, but it potentiates mast cell activation induced by a variety of stimuli. The adenosine receptor type present in mast cells varies depending on the type of mast cell and species studied. A3 receptors potentiate activation of rat basophil leukemia cells (RBL-2H3), a cell line used as a model for rat mast cells (2) .
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vation of these cells appears to be modulated by A2b receptors (3) . A2 receptors appear to mediate activation of human mast cells (4) , but the receptor subtype involved is not known.
The molecular mechanisms by which adenosine potentiates mast cell activation are not fully defined. It was initially proposed that cAMP is involved in this process (5) , but, at least in rat mast cells, the effect of adenosine on mediator release seems to be independent of cAMP (6) . More recently, it has been shown that adenosine activates protein kinase C in mouse bone marrow-derived mast cells. Furthermore, adenosine-induced potentiation of mediator release in these cells was mimicked by low concentrations of direct activators of protein kinase C. High concentrations of these activators, however, produced the opposite effect (7) . Adenosine A3 receptors are also reported to activate phospholipase C via a pertussis toxin-sensitive mechanisms (8) .
Although the functional relevance of adenosine actions on mast cells remains to be established, indirect evidence suggest that adenosine activates mast cells in the human lung, provoking bronchoconstriction (9, 10) . It has been proposed, therefore, that adenosine plays a role in asthma. We believe it is important to determine the adenosine receptor type(s) present in human mast cells, given the disparity found among different species, and to investigate their molecular mechanism of action.
A major limitation in this area of research has been the difficulty in obtaining a pure preparation of human mast cells. Adenosine A2 receptors have been reputed to potentiate activation of partially purified dispersed human lung mast cells (4) . Inhibition of mast cell activation by adenosine has also been reported in human lung fragments (11) , dispersed human lung mast cells (12) , and purified lung mast cells (4) , depending on the concentration of adenosine used, or the time of incubation. The interpretation of these results, however, can be confounded by the potential indirect effects of adenosine on cell types other than mast cells present in these preparations.
A human mast cell line (HMC-1),' derived from a patient with mast cell leukemia, has recently been described ( 13 (14) , which correspond to the human lung mast cell (15) . We have used this cell line to study adenosine receptors and their intracellular signaling pathways.
A major challenge to the hypothesis that adenosine-induced bronchoconstriction plays a role in asthma is the fact that enpro- fylline, a theophylline analogue, is an effective antiasthmatic but is thought to lack adenosine antagonistic properties. However, the effect of enprofylline on A2b receptors has not, to our knowledge, been previously studied. We, therefore, examined the effect of enprofylline on the actions of adenosine on human erythroleukemia cells known to be mediated by A2b receptors (16 [8] [9] . This solution was then applied to a column containing 0.2 ml anion exchange resin (AG 1-X8, formate form, 200-400 mesh; Bio-Rad Laboratories, Richmond, CA). Free inositol and glycerophosphoinositol were eluted with 1.25 ml of H20 and 1 ml of 40 mM ammonium formate/formic acid, pH 5, respectively. Total inositol phosphates were eluted in the single step with 1 ml of 2 M ammonium formate/formic acid, pH 5, and radioactivity was measured by liquid scintillation counting.
Determination of IL-8 secretion. HMC-1 cells were harvested and resuspended to a concentration of 106 cells/ml in serum-free Iscove's media, containing 0.25 U/ml adenosine deaminase. Cells were incubated for 18 h under humidified atmosphere of air/CO2 (19:1) at 37°C with the reagents indicated in Results. At the end of this incubation period the culture media were collected by centrifugation at 100 g for 10 min. IL-8 concentrations were measured in the culture media using an ELISA method (Quantikine; R & D Systems, Minneapolis, MN). We also determined if adenosine potentiated IL-8 production induced by an independent stimulus. PMA (0.6 ng/ml, 1 nM) stimulated IL-8 production to 525±20 pg/ 106 cells (n = 3). NECA (10 MM) increased IL-8 production to 356±20 pg/ 106 cells (n = 3) (Fig. 2 B) . The combination of NECA and PMA stimulated IL-8 production to 2,594±122 pg/ 106 cells (n = 3). To Adenosine agonists produced a dose-dependent accumulation of cAMP in HMC-1 in the absence of forskolin (Fig. 3) . NECA was more efficacious than CGS 21680; at concentrations producing maximal effects (1 mM), NECA produced an eightfold increase in cAMP (to 22 Ca2" through an interaction with more than one receptor site.
In ancillary studies we demonstrated that the NECA-induced increase in FURA-2 fluorescence could not be explained by leakage of the dye to the extracellular space, because we found that 100 ILM NECA did not increase FURA-2 content in the supernatant (data not shown). The increase in intracellular Ca2+ produced by NECA, therefore, can be explained either by an increase in extracellular Ca2+ influx or by mobilization of internal stores. NECA (10 jLM) increased intracellular Ca2' even in cells incubated in the absence of extracellular Ca2 , that is, in a calcium-free medium containing 1 mM EGTA (Fig. 5 A). This indicates that NECA increases intracellular Ca2' by evoking Ca2+ mobilization. On the other hand, CGS 21680 had no effect on intracellular calcium under these conditions (Fig.   5 A) . It should be noted that NECA induced a sustained elevation in Ca2+ levels in the presence of extracellular Ca2+, but, in the absence of extracellular Ca2 , it induced a transient rise in cytoplasmic Ca2+.
We used an additional approach to determine if NECA can stimulate extracellular calcium influxes or intracellular calcium :t: (20) . For these studies Mn2+ was added into Ca2+-free buffer just before each measurement, to a final concentration of 100 ILM. As shown in Fig.   5 B, the addition of NECA to the incubation medium produced an initial increase in the Ca2+ signal, followed by slight quenching of the FURA 2 signal by Mn2+. This suggests that NECA induces an initial mobilization of Ca2+ from intracellular stores and a subsequent (and probably calcium-mediated) cation influx from extracellular media.
We then determined the potential role of G-proteins in adenosine actions on intracellular Ca2+ in HMC-1 cells. Cholera toxin was used as a way to increase the basal activity of the stimulatory guanine nucleotide-binding proteins (Gs) and pertussis toxin was used as a way to block the family of inhibitory guanine nucleotide-binding protein (Gi). Pretreatment of HMC-1 cells with 100 ng/ml cholera toxin or 500 ng/ml pertussis toxin for 24 h had no effect on basal or NECA-stimulated intracellular Ca2+ levels (Fig. 6 ). This effect, therefore, is not mediated by coupling to Gs or Gi proteins. To determine the potential role of cAMP we used forskolin. Forskolin, at concentrations of 10 and 100 MM, had no effect on basal Ca2+ or on the increase in Ca2+ produced by NECA (data not shown). Forskolin effectively stimulated adenylate cyclase at these concentrations. These results, therefore, suggest that NECA-induced rise in intracellular Ca2+ is not mediated by an increase cAMP levels in HMC-1.
Effect of adenosine receptor activation on inositol phosphateformation in HMC-J cells. The major pathway of intracellular calcium mobilization involves phospholipase C activation with phosphoinositide hydrolysis. To determine the role of this pathway on adenosine actions, we measured the accumulation of total inositol phosphates in the presence of 20 mM LiCl. NECA 10 1iM considerably increased the accumulation of inositol phosphates (from 2,402±48 dpm/tube to 3,906±99 dpm/ tube, n = 5, P < 0.001, Fig. 7 ). In contrast, 10 ,.tM CGS 21680 had no effect on levels of inositol phosphates. Enprofylline 300 MM and theophylline 300 AtM blocked the increase in inositol phosphates produced by NECA in HMC-1 cells. Neither antagonist affected basal levels of inositol phosphates. 
Discussion
The hypothesis that adenosine plays a role in asthma was initially suggested by the recognition that theophylline blocks adenosine receptors at concentrations achieved clinically (21, 22) . Even though methylxanthines may have other mechanisms of action in vitro, such as inhibition of phosphodiesterases or mobilization of intracellular calcium, it is believed that these effects require higher concentrations than those clinically achieved in vivo (21) . The antiasthmatic effects of theophylline, therefore, could result from blockade of endogenous adenosine. This assumes, however, that adenosine is able to provoke asthma. In support of this assumption, administration by inhalation of adenosine, or of its precursor AMP, provokes bronchoconstriction in asthmatics but not in normal subjects (23) . Adenosine-induced bronchoconstriction is most likely mediated by activation of mast cells because this effect is blocked not only by adenosine receptor antagonists (9) but also by selective histamine HI blockers (24, 25) and cromolyn sodium (23, 26) . These in vivo findings are in agreement with the observations made by Marquardt and colleagues demonstrating that adenosine activates mast cells in vitro (7, 27) . A major challenge to the hypothesis that adenosine contributes to asthma comes from the "enprofylline paradox." Enprofylline (3-N-propylxanthine) is as effective as theophylline (1, 3, 7, trimethylxanthine) in the treatment of asthma, but was, heretofore, believed not to block adenosine receptors (28, 29) . This assertion, however, derives mostly from studies performed before the recognition of the existence of A2 receptor subtypes. More recently, it has been shown that enprofylline does not compete for A3 receptor binding (30) . To the best of our knowledge, the possibility that enprofylline blocks A2b receptor has been overlooked. Our ( 16) . DPSPX is, to the best of our knowledge, the most potent antagonist of A2b receptors known to date, but a systematic search for methylxanthine analogues with A2b blocking properties has not been undertaken. It is possible that more potent antagonists exist or can be developed. Even though enprofylline is 100-fold less potent than DPSPX, it is the only known selective A2b antagonist to date. Therefore, it can become a useful pharmacological tool to characterize A2b receptors and their functional relevance.
It has been assumed that enprofylline alleviates asthma through mechanisms other than adenosine receptor antagonism. Intravenous enprofylline was found to be less effective than theophylline in blocking adenosine-induced bronchoconstriction ( 31 (Fig. 2 B) . This effect appears to be synergistic rather than additive and is similar to that observed in mouse bone marrow-derived mast cells. Adenylate cyclase is not involved in this process, since potentiation of PMAinduced IL-8 production was not reproduced by 8-Br-cAMP. Further studies are required to define the mechanisms of adenosine-induced potentiation. It should be noted that inhaled adenosine does not require other stimulants to provoke bronchoconstriction in asthmatics. Whether mast cells are in a constant ''preactivated" state in asthma is speculative.
It has been suggested that the recently recognized A3 receptor modulates mast cell activation (40). mRNA encoding A3 receptors is expressed in rat basophil leukemia cells (RBL-2H3), and these receptor types reportedly potentiate activation of these surrogate rat mast cells (2) . However, A3 receptors, while prominent in rat mast cells, have not been shown to be functionally present in mast cells derived from other species. Also, the rat A3 receptor is generally insensitive to methylxanthines, including theophylline (41) . Human (42) and sheep (30) A3 receptors are sensitive to the antagonistic effects of theophylline and other methylxanthines, but they have a low affinity to enprofylline (30) . A3 receptors, therefore, are less likely to be involved in asthma, given the efficacy of enprofylline in the treatment of this disease process. Although we found no evidence for the functional expression of A3 receptors in HMC-1 cells, it remains possible that this receptor type is expressed in other human mast cells.
In summary, our results indicate that the human mast cell line HMC-1 functionally expresses A2b receptors. Their activation leads to increases in phosphoinositide hydrolysis, intracellular calcium mobilization, and IL-8 secretion. Enprofylline is a competitive antagonist of A2b receptors and inhibits adenosinemediated IL-8 secretion in human mast cells. Taken together, these results support the hypothesis that A2b receptors are involved in the putative role of adenosine in asthma. This conclusion, however, is based on the assumptions that antagonism of A2b receptors accounts for the antiasthmatic effects of enprofylline, and that the HMC-1 cell line is an adequate model for adenosine receptors in human lung mast cells. The validity of these assumptions remains to be determined.
